Oncotelic Therapeutics, Inc. (OTLC) stock
OTLCOTCPharmaceutical PreparationsFiscal year ends December 31
$0.02+0.00 (+11.45%)
Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –
Oncotelic Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Oncotelic Therapeutics's total debt was $2.72M at Jun 30, 2025. For fiscal 2024 it was $2.42M, up 37.2% from the year before. The highest annual figure on record is $2.42M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.42M | +37.2% |
| FY2023 | Dec 31, 2023 | $1.77M | +352.5% |
| FY2022 | Dec 31, 2022 | $390.05K | +8.6% |
| FY2021 | Dec 31, 2021 | $359.26K | +278.2% |
| FY2020 | Dec 31, 2020 | $95.00K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | $2.72M | +25.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.58M | +28.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.42M | +37.2% |
| Q3 FY2024 | Sep 30, 2024 | $2.38M | +62.5% |
| Q2 FY2024 | Jun 30, 2024 | $2.16M | +100.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.02M | +241.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.77M | +352.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.47M | +446.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.08M | +266.1% |
| Q1 FY2023 | Mar 31, 2023 | $590.05K | +64.2% |
| Q4 FY2022 | Dec 31, 2022 | $390.05K | +13.6% |
| Q2 FY2022 | Jun 30, 2022 | $268.17K | -64.9% |
| Q1 FY2022 | Mar 31, 2022 | $295.05K | +110.8% |
| Q4 FY2021 | Dec 31, 2021 | $359.26K | +278.2% |
| Q3 FY2021 | Sep 30, 2021 | $343.24K | +390.3% |
| Q2 FY2021 | Jun 30, 2021 | $764.88K | +992.7% |
| Q1 FY2021 | Mar 31, 2021 | $140.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $95.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $70.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $70.00K | – |
See a number that looks wrong?